| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Macitentan |
| Brand | Opsumit® |
| Indication | Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. |
| Assessment Process | |
| Rapid review commissioned | 10/01/2014 |
| Rapid review completed | 27/01/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |